MBS-2320 is under clinical development by Istesso and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect MBS-2320’s likelihood of approval (LoA) and phase transition for Idiopathic Pulmonary Fibrosis took place on 25 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their MBS-2320 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

MBS-2320 overview

MBS-2320 is under development for the treatment of rheumatoid arthritis, ulcerative colitis, multiple myeloma and autoimmune disorders. It is administered through oral route. It is a new molecular entity.

Istesso overview

Istesso formerly known as Modern Biosciences, a subsidiary of IP Group Plc is a pharmaceutical company that offers drug development services. The company provides sources late-stage discovery projects from conducts early proof-of-principle clinical studies, academic institutions, and provides out-licensing services. It develops novel therapeutic agents for the treatment of chronic inflammatory and autoimmune disorders. Istesso offers its project development services through outsourcing the early development work to contract research organizations and research institutions. The company caters its services to the pharmaceutical and biotechnology industry. It serves research institutions, and healthcare professional. Istessois headquartered in London, the UK.

Quick View MBS-2320 LOA Data

Report Segments
  • Innovator
Drug Name
  • MBS-2320
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Immunology
  • Oncology
  • Respiratory
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.